Nitisinone Capsules and Xalkori
Determining the interaction of Nitisinone Capsules and Xalkori and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with crizotinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by crizotinib. The interaction has been studied with midazolam, a probe substrate for CYP450 3A4. In study patients, administration of oral midazolam during treatment with crizotinib (250 mg twice daily for 28 days) resulted in a 3.7-fold increase in mean midazolam systemic exposure (AUC) compared to administration of midazolam alone, suggesting that crizotinib is a moderate inhibitor of CYP450 3A4. MANAGEMENT: Caution is advised when crizotinib is used concomitantly with drugs that undergo metabolism by CYP450 3A4. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever crizotinib is added to or withdrawn from therapy. Concomitant use of crizotinib and substrates of CYP450 3A4 with a narrow therapeutic index (e.g., antiarrhythmic agents, benzodiazepines, ergot derivatives, immunosuppressants, vinca alkaloids) should be avoided if possible. References "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.
Professional:MONITOR: Coadministration with crizotinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by crizotinib. The interaction has been studied with midazolam, a probe substrate for CYP450 3A4. In study patients, administration of oral midazolam during treatment with crizotinib (250 mg twice daily for 28 days) resulted in a 3.7-fold increase in mean midazolam systemic exposure (AUC) compared to administration of midazolam alone, suggesting that crizotinib is a moderate inhibitor of CYP450 3A4.
MANAGEMENT: Caution is advised when crizotinib is used concomitantly with drugs that undergo metabolism by CYP450 3A4. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever crizotinib is added to or withdrawn from therapy. Concomitant use of crizotinib and substrates of CYP450 3A4 with a narrow therapeutic index (e.g., antiarrhythmic agents, benzodiazepines, ergot derivatives, immunosuppressants, vinca alkaloids) should be avoided if possible.
- "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.
Generic Name: nitisinone
Brand name: Orfadin, Nityr
Synonyms: Nitisinone
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Nitisinone Capsules-Xanax
- Nitisinone Capsules-Xanax Oral
- Nitisinone Capsules-Xanax XR
- Nitisinone Capsules-Xanax XR Oral
- Nitisinone Capsules-XaQuil XR
- Nitisinone Capsules-Xarelto
- Xalkori-Nitisinone Oral Suspension
- Xalkori-Nitisinone Tablets
- Xalkori-Nitrek
- Xalkori-Nitric Oxide
- Xalkori-Nitric oxide Inhalation
- Xalkori-Nitric oxide inhalation gas